JP2022512713A5 - - Google Patents

Info

Publication number
JP2022512713A5
JP2022512713A5 JP2021520958A JP2021520958A JP2022512713A5 JP 2022512713 A5 JP2022512713 A5 JP 2022512713A5 JP 2021520958 A JP2021520958 A JP 2021520958A JP 2021520958 A JP2021520958 A JP 2021520958A JP 2022512713 A5 JP2022512713 A5 JP 2022512713A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021520958A
Other languages
English (en)
Japanese (ja)
Other versions
JP7518821B2 (ja
JP2022512713A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/078093 external-priority patent/WO2020079086A1/en
Publication of JP2022512713A publication Critical patent/JP2022512713A/ja
Publication of JP2022512713A5 publication Critical patent/JP2022512713A5/ja
Priority to JP2024108735A priority Critical patent/JP2024138363A/ja
Application granted granted Critical
Publication of JP7518821B2 publication Critical patent/JP7518821B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021520958A 2018-10-16 2019-10-16 重症筋無力症の治療方法 Active JP7518821B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024108735A JP2024138363A (ja) 2018-10-16 2024-07-05 重症筋無力症の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746174P 2018-10-16 2018-10-16
US62/746,174 2018-10-16
PCT/EP2019/078093 WO2020079086A1 (en) 2018-10-16 2019-10-16 Method for the treatment of myasthenia gravis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024108735A Division JP2024138363A (ja) 2018-10-16 2024-07-05 重症筋無力症の治療方法

Publications (3)

Publication Number Publication Date
JP2022512713A JP2022512713A (ja) 2022-02-07
JP2022512713A5 true JP2022512713A5 (https=) 2022-10-24
JP7518821B2 JP7518821B2 (ja) 2024-07-18

Family

ID=68290236

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021520958A Active JP7518821B2 (ja) 2018-10-16 2019-10-16 重症筋無力症の治療方法
JP2024108735A Pending JP2024138363A (ja) 2018-10-16 2024-07-05 重症筋無力症の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024108735A Pending JP2024138363A (ja) 2018-10-16 2024-07-05 重症筋無力症の治療方法

Country Status (14)

Country Link
US (1) US20220144941A1 (https=)
EP (1) EP3866933A1 (https=)
JP (2) JP7518821B2 (https=)
KR (2) KR20260014044A (https=)
CN (1) CN113646051A (https=)
AR (1) AR117653A1 (https=)
AU (1) AU2019361247B2 (https=)
BR (1) BR112021007092A2 (https=)
CA (1) CA3116091A1 (https=)
IL (1) IL282137A (https=)
MA (1) MA53903A (https=)
MX (1) MX2021004351A (https=)
SG (1) SG11202103801UA (https=)
WO (1) WO2020079086A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
IL302516A (en) * 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them
WO2023198806A1 (en) 2022-04-13 2023-10-19 Ose Immunotherapeutics New class of molecules for selective clearance of antibody
AU2023264039A1 (en) * 2022-05-05 2024-11-07 Ra Pharmaceuticals, Inc. Treatment of myasthenia gravis with zilucoplan
EP4536355A1 (en) * 2022-06-11 2025-04-16 Inhibrx Biosciences, Inc. Fcrn-binding polypeptides and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2606378A1 (en) 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
WO2009131702A2 (en) 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011008609A1 (en) 2009-07-14 2011-01-20 Wavetec Vision Systems, Inc. Ophthalmic surgery measurement system
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) * 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
PL3137504T3 (pl) 2014-04-30 2023-10-16 Hanall Biopharma Co., Ltd. Przeciwciało wiążące się z FcRn do leczenia chorób autoimmunologicznych
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
RS64768B1 (sr) 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis

Similar Documents

Publication Publication Date Title
JP2022512713A5 (https=)
JP2021522801A5 (https=)
JP2020002171A5 (https=)
JP2020002172A5 (https=)
IL266756A (en) Human monoclonal antibodies that bind to MASP 2 and suppress MASP-dependent complement activation, methods for their production and uses
Kolesnik et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2017501167A5 (https=)
JP2021191267A5 (https=)
JP2017507900A5 (https=)
JP2009518441A5 (https=)
JP2017503820A5 (https=)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2021510523A5 (https=)
JP2004510752A5 (https=)
JP2019513726A5 (https=)
TWI866304B (zh) 抗EphA4抗體
JP2019505527A5 (https=)
IL272674B2 (en) Preparations for use in the treatment or prevention of graft-versus-graft disease or disseminated intravascular hemorrhage or veno-occlusive disease associated with hematopoietic stem cell transplantation
JP2022517441A (ja) Ｂｔｌａ抗体
KR20200020902A (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
JP2009502139A5 (https=)
JP2018536632A5 (ja) Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子
JP2023089191A5 (https=)
JP2022512851A5 (https=)